Abstract
Since Bast et. al. reported that patients with ovarian carcinoma had elevated levels of CA125 in serum, the attention has been paid to CA125 in serum as a tumor maker.
Serum CA125 levels in 88 patients with gynecological disease were measured. Among 15 patients with malignant ovarian tumor, CA125 values were above 35 U/ml in 80%, and above 65 U/ml in 73%, of serum samples assayed. By increasing the values of CA125 considered normal from 35 to 65 U/ml, the positive rate of benign ovarian tumor and carcinoma of the uterus was markedly reduced. Therefore, it was more efficient as a screening test for gynecological disease that the value of CA125 considered abnormal be above 65 U/ml. Serum CA125 levels were correlated with efficacy of therapy and the clinical course.
